{"id":450,"date":"2019-05-08T15:57:41","date_gmt":"2019-05-08T13:57:41","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=450"},"modified":"2024-04-11T08:10:50","modified_gmt":"2024-04-11T06:10:50","slug":"cancer-colorectal-2","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-cancer\/programa-de-mecanismes-molleculars-i-terapia-experimental-en-oncologia-oncobell\/cancer-colorectal-2\/","title":{"rendered":"C\u00e0ncer Colorectal"},"content":{"rendered":"\n

\n\t\tC\u00e0ncer Colorectal\n\t<\/h1>\n

\n\t\tResum\n\t<\/h3>\n\t

El grup de recerca del C\u00e0ncer colorectal (CRC), liderat per V\u00edctor Moreno i Ramon Salazar, se centra en el descobriment i validaci\u00f3 de noves signatures moleculars de diagn\u00f2stic, pron\u00f2stic i predicci\u00f3 i en la identificaci\u00f3 o optimitzaci\u00f3 de noves dianes terap\u00e8utiques i classificacions moleculars de CRC a trav\u00e9s d’un enfocament integr\u00f2mic, combinant el coneixement de l’epidemiologia gen\u00e8tica, la bioinform\u00e0tica de dades i la farmacologia.<\/p>\n

2760<\/h2>\n

Publicacions<\/h2>\n\t\t\t\t\"colorectal_adenocarcinoma_cytology_intermed_mag\n\t\t\t\t\tL\u00ednies estrat\u00e8giques<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tCaracteritzaci\u00f3 molecular dels tumors digestius a nivell d’an\u00e0lisi gen\u00f2mica, transcript\u00f2mica i prote\u00f2mica (R. Salazar, V.Moreno).
\nConstrucci\u00f3 de signatures moleculars per a la predicci\u00f3 pron\u00f2stica del c\u00e0ncer colorectal (R. Salazar).
\nPrediccions de resposta terap\u00e8utica basades en la detecci\u00f3 de tumors moleculars i la classificaci\u00f3 de subtipus (R. Salazar).
\nNoves estrat\u00e8gies terap\u00e8utiques experimentals per superar la resist\u00e8ncia en el tractament de c\u00e0ncer colorectal (R. Salazar).
\nRecerca, avaluaci\u00f3 i validaci\u00f3 de nous biomarcadors de diagn\u00f2stic en c\u00e0ncer colorectal (V. Moreno).
\nDeterminants gen\u00e8tics i epigen\u00e8tics de la susceptibilitat de CRC i toxicitat per quimioter\u00e0pia (V. Moreno).
\nMillora de la medicina de precisi\u00f3 del c\u00e0ncer i la identificaci\u00f3 de biomarcadors mitjan\u00e7ant l’an\u00e0lisi computacional i la integraci\u00f3 de dades moleculars a gran escala. (X. Sol\u00e9).
\nEstratificaci\u00f3 dels pacients CRC sobre la base de les caracter\u00edstiques moleculars i el nivell d’infiltraci\u00f3 de c\u00e8l\u00b7lules immunes dels seus tumors (C. Santos i R. Sanz-Pamplona).
\nInteraccions microbioma-hoste i c\u00e0ncer colorectal (V. Pimenoff, M.Obon, V. Moreno).
\nValors pron\u00f2stics i predictius de l’ADN tumoral circulant al c\u00e0ncer colorectal metast\u00e0tic (C. Santos)\n\t\t\t\t\t
Publicacions seleccionades<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

Pinato DJ, Aguilar Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom Davis T, Handford J, Sita Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona Garc\u00eda MC, Sharkey R, Garc\u00eda Illescas D, Rizzo G, Perachino M, Saoudi Gonzalez N, Doonga K, Fox L, Rold\u00e1n E, Gaidano G, Ruiz Camps I, Bruna R, Patriarca A, Martinez Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A, OnCovid study G. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study<\/strong>. Lancet Oncol. 2022;23(7):865-875. doi:10.1016\/S1470-2045(22)00273-X.<\/p>\n

Jimenez Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona Bayonas A. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial<\/strong>. Ann. Oncol. 2022;33(8):786-793. doi:10.1016\/j.annonc.2022.04.010.<\/p>\n

Olivera I, Sanz Pamplona R, Bolanos E, Rodriguez I, Etxeberria I, Cirella A, Egea J, Garasa S, Migueliz I, Eguren Santamaria I, Sanmamed MF, Glez Vaz J, Azpilikueta A, Alvarez M, Ochoa MC, Malacrida B, Propper D, de Andrea CE, Berraondo P, Balkwill FR, Teijeira A, Melero I. A therapeutically actionable pro-tumoral axis of cytokines involving interleukin-8, TNFa and IL-1B<\/strong>. Cancer Discov. 2022;12(9):2140-2157. doi:10.1158\/2159-8290.CD-21-1115.<\/p>\n

OnCovid Study G, Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar Company J, Bower M, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Segu\u00ed E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Ottaviani D, Li\u00f1an R, Rossi S, Carmona Garc\u00eda MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Queirolo P, Cruz CA, Saoudi Gonzalez N, Felip E, Roqu\u00e9 Lloveras A, Newsom Davis T, Sharkey R, Rold\u00e1n E, Reyes R, Zoratto F, Earnshaw I, Ferrante D, Marco Hern\u00e1ndez J, Ruiz Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez Vila C, Sanchez de Torre A, Berardi R, Giusti R, Mazzoni F, Guida A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, Van Hemelrijck M, Diamantis N, Gennari A, Cortellini A. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry<\/strong>. JAMA Oncol. 2022;8(1):114-122. doi:10.1001\/jamaoncol.2021.6199.<\/p>\n

Herpers B, Eppink B, James MI, Cortina C, Ca\u00f1ellas Socias A, Boj SF, Hernando Momblona X, Glodzik D, Roovers RC, van de Wetering M, Bartelink Clements C, Zondag van der Zande V, Mateos JG, Yan K, Salinaro L, Basmeleh A, Fatrai S, Maussang D, Lammerts van Bueren JJ, Chicote I, Serna G, Cabellos L, Ram\u00edrez L, Nuciforo P, Salazar R, Santos C, Villanueva A, Stephan Otto Attolini C, Sancho E, Palmer HG, Tabernero J, Stratton MR, de Kruif J, Logtenberg T, Clevers H, Price LS, Vries RGJ, Batlle E, Throsby M. Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR \u00d7 LGR5 bispecific antibody with efficacy in epithelial tumors<\/strong>. Nat. Cancer. 2022;3(4):418-436. doi:10.1038\/s43018-022-00359-0.<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t

FIS22041. Understanding TIL composition and anti-tumor rEactivity in liver metastases from colorectal cancer patients (u-TIL-e)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 130680. 2023-2025. PI: Salazar Soler, Ram\u00f3n \/ Losa Gasp\u00e0 Ferran.<\/p>\n

18INT006. ACRCelerate: Colorectal Cancer Stratified Medicine Network<\/strong>. WORLD CANCER RESEARCH FUND INTERNATIONAL WCRFI. Budget: 78756,34. 2018-2023. PI: Salazar Soler, Ram\u00f3n.<\/p>\n

21FIS026. \u00bfC\u00f3mo influye el microambiente inmune en el patr\u00f3n de diseminaci\u00f3n metast\u00e1sica y supervivencia en<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 123420. 2021-2023. PI: Santos Vivas, Cristina.<\/p>\n

18FIS005. Estudio de las interacciones microbioma-anfitri\u00f3n para la prevenci\u00f3n del c\u00e1ncer colorrectal (Colonbiome)<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 202070. 2018-2022. PI: Moreno Aguado, V\u00edctor; Pimenoff, Ville Nikolai.<\/p>\n

21ACL057. AN OPEN-LABEL STUDY OF THE EFFECT OF TESETAXEL ON THE QTC INTERVAL AND THE EFFECT OF FOOD, ITRACONAZOLE, AND RIFAMPIN ON TESETAXEL PHARMACOKINETICS IN PATIENTS WITH ADVANCED SOLID TUMORS<\/strong>. Budget: 178620. 2021- . PI: Mulet Margalef, N\u00faria.<\/p>\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tParticipaci\u00f3\u00a0en consorcis internacionals MOTRICOLOR (assajos dirigits molecularment\u00a0amb estrat\u00e8gies espec\u00edfiques de tractament\u00a0en pacients amb nous subtipus\u00a0moleculars de c\u00e0ncer colorrectal avan\u00e7at) i FIGI (Utilitzaci\u00f3\u00a0de la gen\u00f2mica funcional per\u00a0informar de les interaccions gen\u00e8tiques del CRC).
\nColon\u00f2mica com a\u00a0plataforma per al descobriment\u00a0de biomarcadors i la caracteritzaci\u00f3\u00a0del CRC.
\nValidaci\u00f3\u00a0cl\u00ednica de ColoPrint\u00ae, una firma gen\u00e8tica pron\u00f2stica de la fase II i el nou\u00a0consens\u00a0de classificaci\u00f3\u00a0de subtipus moleculars (CMS 1-4)\n\t\t\t\t\"Moreno\n

\n\t\tMoreno Aguado, Victor Raul\n\t<\/h4>\n

\n\t\t\n\t\tvmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Salazar\n

\n\t\tSalazar Soler, Ramon\n\t<\/h4>\n

\n\t\t\n\t\trsalazar@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\"Moreno\n

\n\t\tMoreno Aguado, Victor Raul\n\t<\/h4>\n

\n\t\t\n\t\tvmoreno@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Salazar\n

\n\t\tSalazar Soler, Ramon\n\t<\/h4>\n\t\t\t\t\"avatar_idibell_0\"\n

\n\t\tSoler Gonz\u00e1lez, Gemma\n\t<\/h4>\n

\n\t\t\n\t\tgsolerg@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Eric-Duell\"\n

\n\t\tDuell, Eric\n\t<\/h4>\n

\n\t\t\n\t\teduell@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\trsalazar@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"Cristina-Santos\"\n

\n\t\tSantos Vivas, Cristina\n\t<\/h4>\n

\n\t\t\n\t\tcsantos@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\"avatar_idibell_0\"\n

\n\t\tMartinez Villacampa, Mercedes\n\t<\/h4>\n

\n\t\t\n\t\tmmartinezv@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n

\n\t\t\n\t\tColonomics\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tMotricolor\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\tEstudio Colscreen\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@RamonSalazarS\n\t\t<\/a>\n\t<\/h4>\n

\n\t\t\n\t\t@PamplonaSanz\n\t\t<\/a>\n\t<\/h4>\n

\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCap de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadores\/as predoctorales\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSoporte cient\u00edfico\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport de gesti\u00f3\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tCol\u00b7laboradors\/es\t\t\t\t<\/a>\n\t\t\t\t\t\tCap de grup\n\t\t\t\t\t\t\t\t\t\t\t